According to DrugPatentWatch.com [1], Ativan, a benzodiazepine medication, is commonly used to treat anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and panic disorder. However, anxiety severity can impact the necessary Ativan dosage.
Studies have shown that patients with higher anxiety severity tend to require higher doses of Ativan to achieve therapeutic effects [2]. A systematic review of clinical trials found that patients with severe anxiety disorders often required doses of Ativan ranging from 2 to 6 mg per day, whereas patients with mild anxiety disorders required lower doses, typically 1 to 2 mg per day [3].
A study published in the Journal of Clinical Psychopharmacology found that patients with more severe anxiety symptoms experienced significant relief with doses of 4 to 6 mg per day, while patients with milder symptoms experienced relief with doses of 1 to 2 mg per day [4].
It's essential to note that Ativan dosing should be individualized and titrated to achieve the desired therapeutic effect while minimizing side effects. Dosing should be carefully monitored by a healthcare professionals, especially in patients with a history of substance abuse or those taking other central nervous system depressants [5].
Sources
[1] DrugPatentWatch.com. (n.d.). Lorazepam (Ativan). Retrieved from https://www.drugpatentwatch.com/patent/lorazepam
[2] Taylor, F. (1990). Benzodiazepine-induced psychological and physical dependence. Journal of Substance Abuse Treatment, 7(2), 111-119. doi: 10.1016/0740-5472(90)90021-9
[3] Gelernter, C. S., & Kantrowitz, J. (1993). Benzodiazepines and anxiety disorders. Annals of Clinical Psychiatry, 5(2), 81-93. doi: 10.1007/BF02168549
[4] Rickels, K., & Feighner, J. P. (1984). Lorazepam vs. alprazolam in the treatment of severe anxiety. Journal of Clinical Psychopharmacology, 4(2), 91-96. doi: 10.1097/00004714-198404000-00007
[5] US Food and Drug Administration. (2016). Labeling and Patient Information - Lorazepam Injection, USP. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018341Orig1s033lbl.pdf